Primary study · included by 1 review

Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).

Gronhoj 2018 · Grønhøj Christian, Jensen David H, Vester-Glowinski Peter, et al. · International journal of radiation oncology, biology, physics · 2018

Included by

Treatment of Xerostomia with Mesenchymal Stem Cells - A Systematic Review and Meta-Analysis of Clinical Trials.

Non-Cochrane · intervention · 2026 · cited as Grønhøj 2018 (MESRIX) · Results, Table 1; reference 22

Outcome this study informs	Pooled effect	Evidence	Certainty
Unstimulated whole salivary flow rate (UWS) Mesenchymal stem cell (MSC) injection into the salivary glands vs Placebo (saline, saline with albumin, or DMSO) · Short term (up to 6 months; time point closest to 4 months)	MD 0.06 [-0.05, 0.17]	3 studies · 214 participants	GRADE not reported

1 including review in total.